CaseVuBloodhound ABL1 Resistance Panel
At Precipio’s clinical lab, our Bloodhound ABL1 resistance molecular panel is used to detect ABL1 kinase domain mutations in Exons 4, 5, 6, 7, and 8. We use this panel in our clinical lab to reflex BCR-ABL1 positive cases for early detection a possible TKI resistance. This panel streamlines Precipio’s clinical lab work-ups for CML cases. It provides more comprehensive information without the need to employ additional testing platforms that can complicate workflows and lengthen turnaround times.
The Bloodhound ABL1 Resistance panel has been validated as lab developed test at Precipio. It has not been approved by the FDA.
Tech Overview ABL1 Resistance SDS
Development Of The Bloodhound ABL1 Resistance Panel
Precipio’s own clinical hematopathology laboratory developed the Bloodhound ABL1 resistance panel to address the issues of turn-around time and accurate, comprehensive molecular testing for positive BCR-ABL samples. The panel detects ABL1 gene mutation clusters in the kinase domain associated with specific therapeutic indications, enabling the lab to eliminate the need for reflex sequencing of the ABL1 gene, where otherwise necessary.
ABL1 Resistance Molecular Panel Configurations
The ABL1 Resistance panel comes pre-plated or as reagent sets with optimized primers and embedded mutant, NTC, and wild type controls for ABL1 Exons 4, 5, 6, 7, and 8.
3 and 6-sample pre-plated, and vialed free flow configurations are available for the ABL1 Resistance panel. Custom configurations are also possible.
ABL1 Resistance Assay Workflow
Sample preparation is based on standard RNA isolation and cDNA preparation techniques. ABL1 resistance testing can leverage sample preparations from the Bloodhound BCR-ABL1 assay. ABL1 Resistance assay also runs on most HRM-enables RT-PCR instruments. In real time, the instrument captures and uploads data for melt curve analysis of ABL1 exons 4, 5, 6, 7, and 8.